Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 2/20 | 0.39 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 6/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22075047 | 0.90 | PAICS (0.37) | TNIKMETPDE3BPDE3AKCNH2 | |
| SCHEMBL22074968 | 0.89 | FGFR3 (0.38) | FEN1METKDRPDK2 | |
| SCHEMBL30579166 | 0.89 | FGFR3 (0.38) | FEN1METKDRPDK2 | |
| SCHEMBL22074849 | 0.84 | MET (0.47) | FEN1TNIKMETPDE3BPDE3A | |
| SCHEMBL30579112 | 0.81 | FGFR3 (0.39) | METKDR | |
| SCHEMBL22075194 | 0.81 | FGFR3 (0.39) | METKDR | |
| SCHEMBL22074906 | 0.80 | MAPK14 (0.39) | TNIKMETPDE3BPDE3AMAPK14 | |
| SCHEMBL22074976 | 0.80 | MET (0.34) | TNIKMETKCNH2MAPK14KDR | |
| SCHEMBL22075038 | 0.79 | FGFR3 (0.39) | FEN1METMAPK14KDRPDK2 | |
| SCHEMBL30579208 | 0.79 | FGFR3 (0.39) | FEN1METMAPK14KDRPDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210154178-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-20210154178-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-10952996-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-23 | — | — | US | disclosed |
| US-10952996-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200188370-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-18 | — | — | US | disclosed |
| US-20200188370-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10952996-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | FEN1 1230/4885TNIK 176/4885MET 105/4885 |
| US-20210154178-A1 | ALK5 INHIBITORS | ALK, ACVR1, ACVRL1 | FEN1 1230/4885TNIK 176/4885MET 105/4885 |
| US-11730720-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | FEN1 1230/4885TNIK 176/4885MET 105/4885 |
| US-20200188370-A1 | ALK5 INHIBITORS | ALK, ACVR1, ACVRL1 | FEN1 1230/4885TNIK 176/4885MET 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.